A trail of neoadjuvant recombinant human endostatin in combination with docetaxel, epirubicin, and cyclophosphamide in breast cancer patients.

e12033Background: Endostar (EN), recombinant human endostatin, is available to increase apoptosis of tumor cells due to its antiangiogenesis. It also has synergy with chemotherapy medicine. EN or combined with chemotherapy drugs show efficiency in lung cancer, colon cancer or other solid tumors treatments. Here, we evaluated the effect of EN combined with Docetaxel, Epirubicin and Cyclophosphamide (EN+TEC) as a neoadjuvant in treating breast cancer patients. Methods: One hundred and two breast cancer patients confirmed by core biopsy randomly received four cycles neoadjuvant of EN+TEC or TEC only. The clinical complete and partial response rate, pathological complete response rate, Miller & Payne classification (MP score), safety and quality of life were analyzed. Vascular endothelial growth factor (VEGF) and microvessel density (MVD) expressed in tumor tissue were evaluated by immunohistochemistry staining pre- and post-operation. Results: The clinical complete and partial response rate showed no differe...